Susanne Vetsch
Kardiologie · Dept. I
SWISS TAVI
04.11.2024Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI) in Switzerland (SwissTAVI)
Register - 04.11.2024 - 30.12.2040
Laufend
Mitarbeiter/innen: Haager Philipp, Vetsch Susanne, Maeder Micha
A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
01.10.2024
Klinische Forschung - 01.10.2024 - 31.12.2029
Geplant
Projektleitung: Ehl Niklas
Mitarbeiter/innen: Vetsch Susanne
Pulmonary Vein Isolation with Pulsed-Field Ablation with versus without Posterior wall ablation in Patients with Symptomatic Persistent Atrial Fibrillation
17.09.2024A multicentre randomised clinical trial comparing two ablation strategies for the treatment of persistent AF (PVI only or PVI+ posterior wall ablation). IC: persistent AF, (N)OAK EC: atrial interventions, o. atrium >60mm, TAVI, Ml, >NYHA III, LVEF...
Klinische Forschung - 17.09.2024 - 17.09.2027
Laufend
Projektleitung: Franzeck Florian M
Mitarbeiter/innen: Meier Jessica, Vetsch Susanne
Carity Study
01.12.2023CARITY: A targeted approach to ensuring CARe and ActivITY persistence in mid- to older-age persons during and after cardiac rehabilitation following a cardiovascular event or intervention
Klinische Forschung - 01.12.2023 - 01.12.2025
Laufend
Projektleitung: Buser Marc
Mitarbeiter/innen: Vetsch Susanne
Vista Study
23.10.2023prospective, observational, global, multicenter study: The objective of the VISTA Study is to evaluate the safety and performance of the Navitor valve in a realworld setting. This study is intended to satisfy post-market clinical follow-up require...
Klinische Forschung - 23.10.2023 - 30.10.2030
Laufend
Projektleitung: Haager Philipp K.
Mitarbeiter/innen: Vetsch Susanne
Immunopathological pathways underlying myocarditis and inflammatory cardiomyopathy – an exploratory study
24.07.2023Primary objective: Analysis of cardiac antigen- and microbiota-reactive CD4+ T cell and B cell response during development of cardiac inflammation. Secondary objectives: Analysis of clinical data, cardiac imaging and immunological parameters (HLA de...
Klinische Forschung - 24.07.2023 - 24.07.2024
Automatisch geschlossen
Projektleitung: Ludewig Burkhard
Mitarbeiter/innen: Rickli Hans, Maeder Micha, Vetsch Susanne
Oceanic AF
01.06.2023A multicenter, international, randomized, active comparator-controlled, double-blind, doubledummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the preve...
Klinische Forschung - 01.06.2023 - 30.06.2024
Abgeschlossen
Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin, Vetsch Susanne
AmplatzerTM PFO Occluder and AmplatzerTM TalismanTM PFO Occluder PAS (“PFO PAS”) AmplatzerTM PFO Occluder and AmplatzerTM TalismanTM PFO Occluder Post Approval Study
01.06.2023PFO PAS is a singel arm, multinational post-market study in patients with PFO after ischemic stroke (paradoxical embolism). Screening via PFO colloquium. Study Objectives; To demonstrate safety of the Amplatzer PFO Occluder and Amplatzer Talisman P...
Klinische Forschung - 01.06.2023 - 01.06.2028
Laufend
Projektleitung: Chronis Joannis
Mitarbeiter/innen: Meier Jessica, Vetsch Susanne
OCEAN
01.05.2023A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a).
Klinische Forschung - 01.05.2023 - 31.12.2024
Abgebrochen
Projektleitung: Bilz Stefan
Mitarbeiter/innen: Räss Andrea, Rickli Hans, Vetsch Susanne
AMGEN202100057
01.05.2022A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD). The purpose of the study is to characterize the distribution o...
Klinische Forschung - 01.05.2022 - 31.03.2023
Abgeschlossen
Projektleitung: Rickli Hans
Mitarbeiter/innen: Vetsch Susanne, Bilz Stefan, Räss Andrea
SOS AMI Selatogrel
10.01.2022Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjec...
Klinische Forschung - 10.01.2022 - 14.01.2026
Laufend
Projektleitung: Maeder Micha
Mitarbeiter/innen: Vetsch Susanne, Fink Karin
SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)
21.10.2021This study is a single armed, prospective, multi-center, observational study Planned: up to 40 study sites in the EU and selected non-EU-countries
Klinische Forschung - 21.10.2021 - 31.12.2026
Laufend
Projektleitung: Rigger Johannes
Mitarbeiter/innen: Vetsch Susanne, Fink Karin
CARE-HK in HF Registry
30.09.2021This study is a multinational, multicentre, non-interventional, cohort study of assessment and treatment guideline recommendations in HF patient care in a real-world setting.
Klinische Forschung - 30.09.2021 - 31.12.2025
Abgeschlossen
Projektleitung: Maeder Micha
Mitarbeiter/innen: Vetsch Susanne, Schneider Irene
ALFA ROMEO
23.06.2021Atrial fibrillation before and after patent foramen ovale closure study This is a prospective, multicenter, single-arm, observational study assessing the incidence, predictors and prognostic impact of AF occurring before (monitoring phase A) or af...
Klinische Forschung - 23.06.2021 - 23.06.2027
Laufend
Projektleitung: Chronis Joannis
Mitarbeiter/innen: Schneider Irene, Vetsch Susanne
CATCH - Cascade genetic testing of familial hypercholesterolemia: the CATCH multicenter randomized controlled trial
15.12.2020To test in a multicenter open-label randomized controlled trial across Switzerland whether a cascade screening programme for FH, in comparison with usual care, will increase the detection rate of FH within families. The primary outcome will be the...
Klinische Forschung - 15.12.2020 - 31.03.2024
Abgeschlossen
Projektleitung: Rickli Hans
Mitarbeiter/innen: Vetsch Susanne, Schneider Irene
SILENT 2
04.12.2020Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction...
Klinische Forschung - 04.12.2020 - 04.12.2024
Laufend
Projektleitung: Ammann Peter, Kägi Georg
Mitarbeiter/innen: Brenner Roman, Vetsch Susanne, Schneider Irene
PACIFIC AF
21.01.2020Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation Primary Safet...
Klinische Forschung - 21.01.2020 - 07.12.2021
Abgeschlossen
Projektleitung: Rickli Hans
Mitarbeiter/innen: Fink Karin, Vetsch Susanne
AEGIS II_CSL112_3001
07.08.2019A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
Klinische Forschung - 07.08.2019 - 30.08.2020
Abgebrochen
Projektleitung: Rickli Hans
Mitarbeiter/innen: Vetsch Susanne
Flex Nav
22.03.2019This CE Mark study is a prospective, multi-center, single-arm investigational study to support commercialization of the FlexNav™ Delivery System and Loading System in Europe. The design of this clinical investigation is in compliance to ISO standards...
Klinische Forschung - 22.03.2019 - 30.03.2021
Abgeschlossen
Projektleitung: Haager Philipp
Mitarbeiter/innen: Vetsch Susanne
Dissecting the association of anti-microbiota antibodies and auto-reactive T-cells in cardiomyopathy– an exploratory research Project
25.01.2018Prospective research project in which biological material is sampled from humans and health-related personal data is collected (HFV Art 6). To generate further scientific evidence for a potential role of crossreactive antimicrobial T and B cell respo...
Klinische Forschung - 25.01.2018 - 25.08.2021
Abgeschlossen
Projektleitung: Ludewig Burkhard
Mitarbeiter/innen: Maeder Micha, Vetsch Susanne